Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland 4222, Australia.
UVRI-IAVI HIV Vaccine Program, Uganda Virus Research Institute, P.O. Box 49, Entebbe, Uganda.
Metallomics. 2018 Mar 1;10(3):444-454. doi: 10.1039/c7mt00311k. Epub 2018 Feb 21.
Here, the anti-malarial activity of two gold(i) phosphine compounds auranofin and [Au(d2pype)]Cl (where d2pype is 1,2-bis(di-2-pyridylphosphino)ethane), were examined to inform their use as potential drugs and malaria parasite-attenuating agents. In vitro, the gold compounds were active against Plasmodium falciparum and P. knowlesi as well as the rodent parasite P. chabaudi AS. Attenuation of the parasite was observed when mice were inoculated with P. chabaudi AS infected red blood cells treated in vitro with [Au(d2pype)]Cl (1 or 2 μM) or auranofin (2 μM) for 2 or 3 h. Quantitative PCR data showed persistence of low levels of parasite DNA up to 8 days post inoculation. In some experiments, there was microscopically detectable parastiemia following inoculation which subsequently cleared. Following 1 or 3 doses of gold compound-treated parasitized red blood cells (pRBCs), protection was not observed when these mice were subsequently challenged with wild type P. chabaudi AS. In experiments where microscopically detectable parasites were observed following in vivo inoculation, mice were subsequently fully protected against a challenge infection with wildtype parasites. In an infect-and-treat rodent model, the gold compounds were unable to inhibit P. chabaudi AS growth in vivo when administered orally. Gold compounds act via the inhibition of antioxidant systems which are critical in the pathogen's survival from attack by the host oxidants. In vitro, they directly inhibit the parasite thioredoxin reductase, hence the observed suppressive activity. On the other hand, in vivo, the gold compounds may not be readily available for absorption and thus pharmacokinetic studies will be required to further examine drug bioavailability following administration. With structural differences in redox mechanisms of P. falciparum and the human host being identified, gold compounds can be better designed to more efficiently target and selectively inhibit the parasite.
在这里,研究了两种金(i)膦化合物金诺芬和[Au(d2pype)]Cl(其中 d2pype 是 1,2-双(二-2-吡啶基膦)乙烷)的抗疟活性,以了解它们作为潜在药物和疟原虫减毒剂的用途。在体外,这些金化合物对恶性疟原虫和间日疟原虫以及啮齿动物寄生虫伯氏疟原虫 AS 均具有活性。当用 [Au(d2pype)]Cl(1 或 2 μM)或金诺芬(2 μM)处理体外感染的伯氏疟原虫 AS 感染的红细胞接种小鼠时,观察到寄生虫的衰减。定量 PCR 数据显示,接种后 8 天内仍可检测到低水平的寄生虫 DNA。在一些实验中,接种后可在显微镜下检测到寄生虫血症,随后清除。用金化合物处理的寄生虫感染红细胞(pRBC)进行 1 或 3 次剂量处理后,当这些小鼠随后用野生型伯氏疟原虫 AS 进行挑战时,未观察到保护作用。在体内接种后可在显微镜下观察到寄生虫的实验中,随后用野生型寄生虫对这些小鼠进行完全保护。在感染和治疗啮齿动物模型中,当口服给予时,金化合物无法抑制体内伯氏疟原虫 AS 的生长。金化合物通过抑制抗氧化系统起作用,抗氧化系统对病原体从宿主氧化剂的攻击中存活至关重要。在体外,它们直接抑制寄生虫硫氧还蛋白还原酶,因此观察到抑制活性。另一方面,在体内,金化合物可能不易被吸收,因此需要进行药代动力学研究以进一步检查给药后药物的生物利用度。由于已经确定了恶性疟原虫和人类宿主的氧化还原机制的结构差异,因此可以更好地设计金化合物以更有效地靶向和选择性抑制寄生虫。